9 Meters Biopharma Inc - ESG Rating & Company Profile powered by AI
This ESG assessment for 9 Meters Biopharma Inc represents the company's reporting of the UN Sustainable Development Goals. The report of 9 Meters Biopharma Inc leverages data from across the internet and also from public filings by 9 Meters Biopharma Inc. Browse to the bottom of the page for potential risks for 9 Meters Biopharma Inc based on sector, geography and marketcap.
9 Meters Biopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 2.7, social score of 1.6 and governance score of 2.0.
2.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1551 | Voyager Life PLC | 2.2 | Medium |
1551 | Source Natural Foods and Herbal Supplements Ltd | 2.2 | Medium |
1571 | 9 Meters Biopharma Inc | 2.1 | Medium |
1571 | Cerevel Therapeutics Holdings Inc | 2.1 | Medium |
1571 | Charlotte's Web Holdings Inc | 2.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does 9 Meters Biopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Does 9 Meters Biopharma Inc disclose current and historical energy intensity?
Does 9 Meters Biopharma Inc report the average age of the workforce?
Does 9 Meters Biopharma Inc reference operational or capital allocation in relation to climate change?
Does 9 Meters Biopharma Inc disclose its ethnicity pay gap?
Does 9 Meters Biopharma Inc disclose cybersecurity risks?
Does 9 Meters Biopharma Inc use carbon offsets or credits exclusively for residual emissions (typically less than ~0.5–5% of total emissions)?
Does 9 Meters Biopharma Inc offer flexible work?
Does 9 Meters Biopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does 9 Meters Biopharma Inc disclose the number of employees in R&D functions?
Does 9 Meters Biopharma Inc plan to change its portfolio composition to lower the emissions intensity of its energy mix (e.g., by shifting from oil to gas, or by adding lower-carbon options like hydrogen, e-fuels, bioenergy, etc.)?
Does 9 Meters Biopharma Inc conduct supply chain audits?
Does 9 Meters Biopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does 9 Meters Biopharma Inc conduct 360 degree staff reviews?
Does 9 Meters Biopharma Inc disclose the individual responsible for D&I?
Does 9 Meters Biopharma Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does 9 Meters Biopharma Inc disclose current and / or historical scope 2 emissions?
Does 9 Meters Biopharma Inc disclose water use targets?
Does 9 Meters Biopharma Inc have careers partnerships with academic institutions?
Did 9 Meters Biopharma Inc have a product recall in the last two years?
Does 9 Meters Biopharma Inc disclose incidents of discrimination?
Does 9 Meters Biopharma Inc allow for Work Councils/Collective Agreements to be formed?
Has 9 Meters Biopharma Inc issued a profit warning in the past 24 months?
Does 9 Meters Biopharma Inc disclose parental leave metrics?
Does 9 Meters Biopharma Inc disclose climate scenario or pathway analysis?
Does 9 Meters Biopharma Inc disclose current and / or historical scope 1 emissions?
Does 9 Meters Biopharma Inc explicitly state that carbon offsets or credits are separate from its emissions-reduction progress or that they are not counted toward its emissions-reduction targets?
Are Operating Expesnses linked to emissions reduction?
Does 9 Meters Biopharma Inc disclose the pay ratio of women to men?
Does 9 Meters Biopharma Inc support suppliers with sustainability related research and development?
Does 9 Meters Biopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does 9 Meters Biopharma Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is 9 Meters Biopharma Inc involved in embryonic stem cell research?
Does 9 Meters Biopharma Inc disclose GHG and Air Emissions intensity?
Does 9 Meters Biopharma Inc disclose its waste policy?
Does 9 Meters Biopharma Inc report according to TCFD requirements?
Does 9 Meters Biopharma Inc plan to mitigate emissions from future new production assets through measures such as electrifying equipment, carbon capture and storage, repurposing waste gas, methane leak detection and repair, eliminating flaring, etc.?
Does 9 Meters Biopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does 9 Meters Biopharma Inc disclose energy use targets?
Does 9 Meters Biopharma Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does 9 Meters Biopharma Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for 9 Meters Biopharma Inc
These potential risks are based on the size, segment and geographies of the company.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.